Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Treatment decision guided by CTC count may improve long-term outcomes for mBC

The future of precision oncology

The concept of pan-tumour therapeutics

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Monitoring and evaluation as a tool for quality improvement in cancer screening

Cloud software for helping build quality assurance in radiotherapy

UICC / WHO Policy dialogue: Maintaining cancer care in times of conflict and environmental emergencies

ARCHERY trial: Testing AI for radiotherapy

Systemic anti-cancer performance matrix